• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Neurotech International

Neurotech International

ASX:NTI

  • Home
  • Corporate
    • Board and Management
    • Corporate Directory
    • Corporate Governance
    • Corporate Videos
  • Development Programs
    • Biopharmaceutical Trials
    • Group Strategy and Target Markets
    • NTI164
    • Clinical Trials
    • Pathways to Commercialisation
  • Investors
    • Investor Dashboard
    • ASX Announcements
    • Investor Conference Calls  
    • Company Reports
    • Presentations
    • Research
    • News & Media
    • Fact Sheets
    • Analyst Reports
    • Right to Receive Documents
  • Contact

Stockhead: Dual strategy positions NTI164 for autism and Rett markets

7 October 2025 News & Media

Read the full article here

Footer

Suite 102 / Level 1, 55 Collins Street
Melbourne VIC 3000
Australia

moc.l1761115213anoit1761115213anret1761115213nihce1761115213torue1761115213n@ofn1761115213i1761115213

+61 (3) 9498 3132

Subscribe to our latest announcements

"*" indicates required fields

Name*
This field is for validation purposes and should be left unchanged.

Copyright © 2025 Neurotech International • Site by White Noise Communications

Download prospectus